SCHEMBL4380818

SCHEMBL4380818

CC(C)(C)OC(=O)n1c(CON)nc2cc(Cl)cnc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXA2R P21731 2/20 0.42
TTK P33981 2/20 0.33
NR1H2 P55055 3/20 0.32
HSP90AA1 P07900 1/20 0.32
HSP90AB1 P08238 1/20 0.32
GABRG2 P18507 2/20 0.32
GABRB3 P28472 2/20 0.32
GABRA5 P31644 2/20 0.32
AURKA O14965 1/20 0.32
CDK2 P24941 1/20 0.32
FAAH O00519 1/20 0.32
BRD4 O60885 1/20 0.31
IRAK4 Q9NWZ3 1/20 0.31
NR1H3 Q13133 1/20 0.30
STS P08842 1/20 0.30
CA12 O43570 1/20 0.30
CA9 Q16790 1/20 0.30
GABRA1 P14867 1/20 0.30
GABRA2 P47869 1/20 0.30
GABRA6 Q16445 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4382620 0.83 TBXA2R (0.42) TBXA2RBRD4
SCHEMBL4379489 0.79 LMNA (0.40) TBXA2R
SCHEMBL13588903 0.71 TBXA2R (0.41) TBXA2RNR1H2
SCHEMBL21292742 0.69 FGFR1 (0.46) TBXA2RHSP90AA1HSP90AB1IRAK4
SCHEMBL4149003 0.68 TBXA2R (0.44) TBXA2RNR1H2
SCHEMBL22894785 0.67 TBXA2R (0.45) TBXA2RFAAH
SCHEMBL6221657 0.67 TBXA2R (0.47) TBXA2RNR1H2HSP90AA1HSP90AB1FAAH
SCHEMBL27043949 0.66 HTR6 (0.38) TBXA2RNR1H2HSP90AA1HSP90AB1GABRG2
SCHEMBL25909811 0.64 HSP90AA1 (0.41) HSP90AA1HSP90AB1GABRG2GABRB3GABRA5
SCHEMBL6224033 0.64 BRD4 (0.44) TBXA2RFAAHBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
EP-2040698-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2009-04-01 EP disclosed
WO-2008008398-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 TBXA2R 328/4885TTK 2478/4885NR1H2 419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.